Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia In Vitro Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (c(RGDfV)) (35 nM, 4-24 h) disruptes the adhesion and migration between the tumor cells and the matrix, induces the leukemia cells to leave the protective microenvironment and increases their sensitivity to cell cycle-dependent agents. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: MV4-11 cells Concentration: 35 nM Incubation Time: 24 h Result: Affected the leukemia cell cycle, decreased the G0/G1 phase of leukemia cells in the 3D and 2D culture systems and increased the S phase of leukemia cells in the 3D and 2D culture systems. Apoptosis AnalysisCell Line: MV4-11 cells Concentration: 35 nM Incubation Time: 24 h Result: Increased the apoptosis rates. Form:Solid IC50& Target:αvβ3